Trial Profile
Randomised, double-blind, placebo-controlled efficacy and safety study of IGF-I trophic factor in Friedreich's Ataxia. [ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TROFICO IGF-I EN LA ATAXIA DE FRIEDREICH]
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2012
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary)
- Indications Friedreich's ataxia
- Focus Therapeutic Use
- 15 Mar 2012 New trial record